The History and Development of HER2 Inhibitors

HER2 is highly expressed in a variety of malignant tumors and affects the prognosis of patients, making it a highly sensitive target for cancer therapy. Since the approval of the first HER2 inhibitor, trastuzumab, in 1998, HER2-targeted drugs have rapidly evolved. Currently, targeting HER2 drugs mai...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Xiaohui, Gong, Chen, Zhang, Yinan, Xiong, Huihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610116/
https://www.ncbi.nlm.nih.gov/pubmed/37895921
http://dx.doi.org/10.3390/ph16101450
_version_ 1785128176168468480
author Xia, Xiaohui
Gong, Chen
Zhang, Yinan
Xiong, Huihua
author_facet Xia, Xiaohui
Gong, Chen
Zhang, Yinan
Xiong, Huihua
author_sort Xia, Xiaohui
collection PubMed
description HER2 is highly expressed in a variety of malignant tumors and affects the prognosis of patients, making it a highly sensitive target for cancer therapy. Since the approval of the first HER2 inhibitor, trastuzumab, in 1998, HER2-targeted drugs have rapidly evolved. Currently, targeting HER2 drugs mainly include monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs). This article reviews the development of HER2 inhibitors for various tumors over the past 20 years.
format Online
Article
Text
id pubmed-10610116
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106101162023-10-28 The History and Development of HER2 Inhibitors Xia, Xiaohui Gong, Chen Zhang, Yinan Xiong, Huihua Pharmaceuticals (Basel) Review HER2 is highly expressed in a variety of malignant tumors and affects the prognosis of patients, making it a highly sensitive target for cancer therapy. Since the approval of the first HER2 inhibitor, trastuzumab, in 1998, HER2-targeted drugs have rapidly evolved. Currently, targeting HER2 drugs mainly include monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs). This article reviews the development of HER2 inhibitors for various tumors over the past 20 years. MDPI 2023-10-12 /pmc/articles/PMC10610116/ /pubmed/37895921 http://dx.doi.org/10.3390/ph16101450 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Xia, Xiaohui
Gong, Chen
Zhang, Yinan
Xiong, Huihua
The History and Development of HER2 Inhibitors
title The History and Development of HER2 Inhibitors
title_full The History and Development of HER2 Inhibitors
title_fullStr The History and Development of HER2 Inhibitors
title_full_unstemmed The History and Development of HER2 Inhibitors
title_short The History and Development of HER2 Inhibitors
title_sort history and development of her2 inhibitors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610116/
https://www.ncbi.nlm.nih.gov/pubmed/37895921
http://dx.doi.org/10.3390/ph16101450
work_keys_str_mv AT xiaxiaohui thehistoryanddevelopmentofher2inhibitors
AT gongchen thehistoryanddevelopmentofher2inhibitors
AT zhangyinan thehistoryanddevelopmentofher2inhibitors
AT xionghuihua thehistoryanddevelopmentofher2inhibitors
AT xiaxiaohui historyanddevelopmentofher2inhibitors
AT gongchen historyanddevelopmentofher2inhibitors
AT zhangyinan historyanddevelopmentofher2inhibitors
AT xionghuihua historyanddevelopmentofher2inhibitors

Ejemplares similares